Intracellular transport of recombinant adeno-associated virus vectors.

Gene Therapy
M Nonnenmacher, Thomas Weber

Abstract

Recombinant adeno-associated viral vectors (rAAVs) have been widely used for gene delivery in animal models, and are currently evaluated for human gene therapy after successful clinical trials in the treatment of inherited, degenerative or acquired diseases, such as Leber congenital amaurosis, Parkinson disease or heart failure. However, limitations in vector tropism, such as limited tissue specificity and insufficient transduction efficiencies of particular tissues and cell types, still preclude therapeutic applications in certain tissues. Wild-type adeno-associated viruses (AAVs) are defective viruses that require the presence of a helper virus to complete their life cycle. On the one hand, this unique property makes AAV vectors one of the safest available viral vectors for gene delivery. On the other, it also represents a potential obstacle because rAAV vectors have to overcome several biological barriers in the absence of a helper virus to transduce successfully a cell. Consequently, a better understanding of the cellular roadblocks that limit rAAV gene delivery is crucial and, during the last 15 years, numerous studies resulted in an expanding body of knowledge of the intracellular trafficking pathways of rAAV vectors. Thi...Continue Reading

References

Jun 1, 1966·Proceedings of the National Academy of Sciences of the United States of America·M D HogganW P Rowe
Oct 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·P L Hermonat, N Muzyczka
Mar 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·R J SamulskiN Muzyczka
Feb 15, 1995·Structure·M S Chapman, M G Rossmann
Jun 6, 1995·Proceedings of the National Academy of Sciences of the United States of America·D W RussellA D Miller
Jul 11, 1996·Nature·C LamazeS L Schmid
Feb 18, 1997·Proceedings of the National Academy of Sciences of the United States of America·D D KoeberlA D Miller
Oct 6, 1997·Proceedings of the National Academy of Sciences of the United States of America·K QingA Srivastava
Jun 13, 1998·Human Gene Therapy·J S BartlettT J McCown
Jan 12, 1999·Nature Medicine·C SummerfordR J Samulski
Nov 13, 1999·Journal of Virology·D DuanJ F Engelhardt
Dec 28, 1999·Annual Review of Cell and Developmental Biology·D Görlich, U Kutay
Feb 23, 2000·Journal of Virology·J S BartlettR J Samulski
Feb 26, 2000·Proceedings of the National Academy of Sciences of the United States of America·B L DavidsonJ A Chiorini
Apr 28, 2000·Science·M Cavazzana-CalvoA Fischer
Jun 7, 2000·The Journal of Clinical Investigation·D DuanJ F Engelhardt
Oct 4, 2000·Physiological Genomics·M RichterM D Allen
Dec 22, 2000·Molecular Therapy : the Journal of the American Society of Gene Therapy·H ChaoC E Walsh
Mar 23, 2001·The Journal of Biological Chemistry·R W WaltersJ Zabner

❮ Previous
Next ❯

Citations

Feb 28, 2013·Human Gene Therapy Methods·Vedell Louis JeuneThomas Weber
May 18, 2012·Journal of Virology·Brittney L GurdaMavis Agbandje-McKenna
Jul 13, 2012·Journal of Virology·Shen ShenAravind Asokan
Mar 5, 2013·The Journal of Clinical Investigation·Chengwen LiR Jude Samulski
Jan 16, 2013·PloS One·Balaji BalakrishnanGiridhara R Jayandharan
Jul 8, 2014·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Shervin GholizadehDavid R Hampson
Jul 25, 2014·Chemical Communications : Chem Comm·Maximilian HörnerWilfried Weber
Aug 16, 2014·Progress in Retinal and Eye Research·Ivana TrapaniAlberto Auricchio
Nov 3, 2014·Annual Review of Virology·R Jude Samulski, Nicholas Muzyczka
Sep 21, 2013·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Markus RothermelMatt Wachowiak
Jan 1, 2015·Expert Opinion on Orphan Drugs·Eric Hastie, R Jude Samulski
Jun 24, 2014·Expert Opinion on Drug Delivery·Babak Bakhshinejad, Majid Sadeghizadeh
Jan 13, 2016·Human Gene Therapy Methods·Kyle ChamberlainThomas Weber
Jan 28, 2016·Nature·S PillayJ E Carette
Aug 31, 2016·Nature Microbiology·Sabrina Sun, David V Schaffer
Dec 18, 2015·The Journal of Physical Chemistry. B·Mercedes Hernando-PérezBogdan G Dragnea
Oct 17, 2015·Acta Biomaterialia·Ana Rey-Rico, Magali Cucchiarini
Aug 21, 2015·Current Opinion in Pharmacology·Leszek LisowskiIan Edward Alexander
Oct 27, 2015·Trends in Biotechnology·Christian J BuchholzHildegard Büning
Sep 12, 2013·Reviews in Medical Virology·Sangeetha HareendranGiridhara R Jayandharan
Apr 16, 2016·Molecular Therapy : the Journal of the American Society of Gene Therapy·Candace SummerfordR Jude Samulski
Apr 4, 2015·Human Gene Therapy·Uta GriesenbachEric W F W Alton
Jun 9, 2015·Molecular Therapy. Methods & Clinical Development·Kleopatra RaptiRoger J Hajjar
Dec 2, 2015·PLoS Pathogens·Christina HölscherMartin Müller
Apr 26, 2016·Oral Diseases·John A Chiorini
Jul 28, 2016·Current Opinion in Virology·Dongsheng Duan
Oct 19, 2016·Journal of Controlled Release : Official Journal of the Controlled Release Society·Joana SaraivaLuis Pereira de Almeida

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Related Papers

Molecular Therapy : the Journal of the American Society of Gene Therapy
Brian R Schultz, Jeffrey S Chamberlain
Molecular Therapy : the Journal of the American Society of Gene Therapy
Knut StiegerFabienne Rolling
Molecular Therapy : the Journal of the American Society of Gene Therapy
Francesca SimonelliAlberto Auricchio
© 2022 Meta ULC. All rights reserved